Severe Ebola virus disease with vascular leakage and multiorgan failure: Treatment of a patient in intensive care

The Lancet

Volumn 385, Issue 9976, 2015, Pages 1428-1435

  Wolf, Timo ^a   Kann, Gerrit ^a   Becker, Stephan ^b   Stephan, Christoph ^a   Brodt, Hans Reinhardt ^a   De Leuw, Philipp ^a   Grünewald, Thomas ^c   Vogl, Thomas ^a   Kempf, Volkhard A J ^a   Keppler, Oliver T ^a   Zacharowski, Kai ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Klinikum St Georg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMIODARONE; AMYLASE; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; COLISTIN; DIPYRONE; FAVIPIRAVIR; FIBRIN DERIVATIVE; FLUCONAZOLE; FX 06; INTERLEUKIN 6; LINEZOLID; MEROPENEM; METRONIDAZOLE; MORPHINE; NORADRENALIN; ORAL REHYDRATION SOLUTION; PARACETAMOL; PEPTIDE DERIVATIVE; PHOSPHATE; RINGER LACTATE SOLUTION; SCOPOLAMINE BROMIDE; TIGECYCLINE; UNCLASSIFIED DRUG; AMIDE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN BBETA (15-42); PEPTIDE FRAGMENT; PYRAZINE DERIVATIVE;

ABDOMINAL PAIN; ABDOMINAL PRESSURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALOSIS; AMYLASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BLEEDING; CANDIDA PARAPSILOSIS; CANDIDIASIS; CAPILLARY LEAK SYNDROME; CASE REPORT; CATHETER COMPLICATION; CENTRAL VENOUS CATHETER; CHOLECYSTITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTINUOUS HEMODIAFILTRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EBOLA HEMORRHAGIC FEVER; ECHOCARDIOGRAPHY; ECHOGRAPHY; ERYTHROCYTE URINE LEVEL; FEVER; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; HEART EJECTION FRACTION; HUMAN; HYPERVENTILATION; HYPONATREMIA; HYPOTENSION; IC50; INTENSIVE CARE; INTESTINAL EDEMA; KIDNEY FAILURE; LENGTH OF STAY; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW DRUG DOSE; LUNG EDEMA; LUNG INJURY; LUNG INSUFFICIENCY; MALAISE; MALE; MEDICAL HISTORY; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA AND VOMITING; NEUTROPHILIA; NONINVASIVE VENTILATION; OXYGEN THERAPY; PARALYTIC ILEUS; PATIENT CARE; PERICARDIAL EFFUSION; PERICYSTIC EDEMA; PERITONITIS; PHOSPHATE BLOOD LEVEL; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RESPIRATORY FAILURE; SCORING SYSTEM; SELF MEDICATION; SIERRA LEONE; TACHYCARDIA; THORAX RADIOGRAPHY; THREE LAYERED GALLBLADDER; THROAT CULTURE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD VESSEL; ENDOTRACHEAL INTUBATION; HEMORRHAGIC FEVER, EBOLA; PATHOPHYSIOLOGY; PROCEDURES; PULMONARY EDEMA; RENAL INSUFFICIENCY; RESPIRATORY INSUFFICIENCY;

ADULT; AMIDES; AMIODARONE; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BLOOD VESSELS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMORRHAGIC FEVER, EBOLA; HUMANS; INTENSIVE CARE; INTUBATION, INTRATRACHEAL; MALE; MULTIPLE ORGAN FAILURE; PATIENT ISOLATION; PEPTIDE FRAGMENTS; PULMONARY EDEMA; PYRAZINES; RADIOGRAPHY, THORACIC; RENAL INSUFFICIENCY; RESPIRATORY INSUFFICIENCY;

EID: 84928697923     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62384-9     Document Type: Article

References (20)

1. WHO. Ebola response roadmap situation report. Geneva: World Health Organization, 2014. http://apps.who.int/iris/bitstream/10665/137510/1/roadmapsitrep-5Nov14-eng.pdf?ua-1 (accessed Nov 6, 2014).
2. Marshall GL, Mehta AK, Varkey J.B., et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014; published online Nov 12. DOI:10.1056/NEJMoa1409838.
3. Parra MJ, Salmeron OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. N Engl J Med 2014; published online Nov 19. DOI:10.1056/NEJMc1412662.
4. Kreuels B, Wichmann D, Emmerich P., et al. A case of severe Ebola virus infection complicated by Gram-negative septicaemia. N Engl J Med 2014; published online Oct 22. DOI:10.1056/NEJMoa1411677.
5. Gehring G, Rohrmann K, Atecnhong K., et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014; 69: 2123-31.
6. Murray JF, Matthay MA, Luce J, et al An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 720-23.
7. Ware LB, Neyrinck A, O Neal HR, et al. California transplant donor network. Clin Transplant 2012; 26: 665-71.
8. Schieffelin J, Shaffer JG, Goba A, et al Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med, 2014; published online Oct 29. DOI:10.1056/NEJMoa1411680.
9. Manenzhe RI, Zar HJ, Nicoll M.P., Kaba M. The spread of carbapenemase-producing bacteria in Africa: a systematic review. J Antimicrob Chemother 2014; published online Sept 26. DOI:10.1093/jac/dku356.
10. Rowe AK, Bertolli J, Khan A.S., et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis; 1999; 179 (suppl 1): S28-35.
11. Endo T, Kushimoto S, Yamanouchi S., et al. Limitations of global end-diastolic volume index as a parameter of cardiac preload in the early phase of severe sepsis: a subgroup analysis of a multicenter, prospective observational study. J Intensive Care 2013; 1: 11.
12. Feldmann H, Geisbert TW Ebola haemorrhagic fever. Lancet 2011; 377: 849-62.
13. Srikiatkhachorn A, Kelley JF Endothelial cells in dengue hemorrhagic fever. Antiviral Res 2014; 109: 160-70.
14. Baluna R, Vitetta ES Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997; 3: 117-32.
15. Hamada Y, Kawachi K, Tsunooka N., Nakamura Y, Takano S, Imagawa H. Capillary leakage in cardiac surgery with cardiopulmonary bypass. Asian Cardiovasc Thorac Ann 2004; 12: 193-97.
16. Czikora I, Sridhar S, Gorshkov B., et al. Protective effect of growth hormone-releasing hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction. Front Physiol 2014; 5: 259.
17. 15-42 preserves endothelial barrier function in shock. PLoS One 2009; 4: e5391.
18. Atar D, Petzelbauer P, Schwitter J., et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009; 53: 720-29.
19. Martines RB, Ng DL, Greer P.W., et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg Viruses. J Pathol 2014; published online Oct 9. DOI:10.1002/path.4456
20. Amlot PL, Stone MJ, Cunningham D, et al A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624-33.